|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus.
|
31116791 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overcoming Challenges of Hepatitis C Virus Envelope Glycoprotein Production in Mammalian Cells.
|
30593635 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, this effort has proven challenging because HCV evades neutralizing antibodies (NAbs) through molecular features of viral envelope glycoprotein E2, including hypervariable region 1 (HVR1) and N-linked glycans.
|
31040211 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cumulative evidence supports the importance of antibodies targeting the HCV E2 envelope glycoprotein to facilitate viral clearance.
|
30651366 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we evaluated two different semi-synthetic archaeosome formulations as an adjuvant to the E1/E2 HCV envelope protein in a murine model and compared antigen-specific humoral (levels of anti-E1/E2 IgG and HCV pseudoparticle neutralization) and cellular responses (numbers of antigen-specific cytokine-producing T cells) to those generated with adjuvant formulations composed of mimetics of commercial adjuvants including a squalene oil-in-water emulsion, aluminum hydroxide/monophosphoryl lipid A (MPLA) and liposome/MPLA/QS-21.
|
31816920 |
2019 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The high variation in envelope protein sequence among HCV isolates necessitates the inclusion of several isolates, spanning the major genotypes of HCV, in order to make strong conclusions concerning the cross-reactive neutralization potential of a given antibody.
|
30593643 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is a sensitive and robust method for future studies investigating B cell responses against the HCV Envelope protein.
|
31226262 |
2019 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been recently reported, using in vitro studies, that the herpes simplex virus 1 (HSV-1) encoded envelope glycoprotein B (gB1) interacts with cell surface toll-like receptor 2 (TLR2) and induces the secretion of interleukin-8 (IL8), a representative marker of inflammatory cytokine activation.
|
31487910 |
2019 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus spread between epithelial cells is mediated by virus tegument and envelope protein complexes including gE/gI and pUL51/pUL7. pUL51 interacts with both pUL7 and gE/gI in infected cells.
|
31493658 |
2019 |
|
Influenza
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting of antigens to the dendritic cell (DC) molecule Clec9A has been shown to enhance antibody affinity and titers for model antigens, and influenza and enterovirus antigens, and may be advantageous for immunogens that otherwise fail to elicit antibodies with sufficient titers and breadth for broad protection, such as the envelope protein (Env) of HIV.
|
31430333 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We have recently shown that the distal portion of the α9 helix in the C-terminal heptad repeat of X4-tropic HXB2 Env plays a critical role in the late-stage membrane fusion and viral infection.
|
30737278 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We will also highlight the effective cooperation between innate and adaptive immunity to achieve the synergistic control of viral infection by targeting viral envelope protein and checking viral escape.
|
30935048 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Deletion of the Env cytoplasmic tail improved the efficiency with which the SOS Env supported virus infection in a reducing environment.
|
30944182 |
2019 |
|
Virus Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Zika (ZIKV) and dengue (DENV) virus infections elicit a robust but cross-reactive antibody response against the viral envelope protein, while antibody responses against non-structural proteins (NS) are more virus specific.
|
30902827 |
2019 |
|
Zika Virus Infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
More specifically, we identified an epitope on Zika virus (ZIKV) envelope protein domain III (EDIII) that is buried in the full-length envelope protein but becomes exposed in recombinant EDIII.
|
31189716 |
2019 |
|
Zika Virus Infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we established a competitive amplified luminescent proximity homogeneous assay (ALPHAscreen) to identify small molecule inhibitors targeting the envelope protein of Zika virus (Zika E).
|
30771406 |
2019 |
|
Zika Virus Infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanistic study indicated that gossypol could neutralize ZIKV infection by targeting the envelope protein domain III (EDIII) of ZIKV.
|
31684080 |
2019 |
|
Zika Virus Infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
The envelope protein of Zika virus (ZIKV) exists as a dimer on the mature viral surface and is an attractive antiviral target because it mediates viral entry.
|
31138647 |
2019 |
|
Zika Virus Infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, the present study demonstrates that the lateral ridge region of the envelope protein is likely an immunodominant, neutralizing epitope.<b>IMPORTANCE</b> Zika virus (ZIKV) is a global health threat causing severe disease in humans, including microcephaly in newborns and Guillain-Barré syndrome in adults.
|
31043537 |
2019 |
|
Zika Virus Infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
The population coverage was pan world and nearly 70% identity of the peptide was found in the Zika virus envelope protein.
|
31300121 |
2019 |
|
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first two coding-complete genomes provided actionable information in real-time for the deployment of the rVSVΔG-ZEBOV-GP Ebola virus envelope glycoprotein vaccine, available therapeutics, and sequence-based diagnostic assays.
|
31000464 |
2019 |
|
Hemorrhagic Fever, Ebola
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of Gamma Irradiation on the Antibody Response Measured in Human Serum from Subjects Vaccinated with Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine.
|
31162004 |
2019 |
|
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ZINC58935541 molecule also showed a strong binding affinity towards the receptor cavity of Ebola virus envelope glycoprotein when simulated for 1.2 ns.
|
30786763 |
2019 |
|
Hemorrhagic Fever, Ebola
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EBOV glycoprotein (GP<sub>1,2</sub>) is the sole viral envelope protein and a major component of immunogenicity; it is encoded by the <i>GP</i> gene along with two truncated versions: soluble GP (sGP) and small soluble GP (ssGP). sGP is, in fact, the primary product of the <i>GP</i> gene, and it is secreted in abundance during EBOV infection.
|
31683550 |
2019 |
|
West Nile viral infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, this new approach results in rapid virus inactivation while greatly improving the maintenance of WNV-specific neutralizing epitopes mapped across the three structural domains of the WNV envelope protein.
|
30606462 |
2019 |